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Professional antigen-presenting cells (APCs) such as conventional dendritic cells (DCs)
process protein antigens to MHC-bound peptides and then present the peptide–MHC
complexes to T cells. In addition to this canonical antigen presentation pathway, recent
studies have revealed that DCs and non-APCs can acquire MHC class I (MHCI) and/or MHC
class II (MHCII) from neighboring cells through a process of cell–cell contact-dependent
membrane transfer called trogocytosis.These MHC-dressed cells subsequently activate or
regulate T cells via the preformed antigen peptide–MHC complexes without requiring any
further processing. In addition to trogocytosis, intercellular transfer of MHCI and MHCII can
be mediated by secretion of membrane vesicles such as exosomes from APCs, generating
MHC-dressed cells. This review focuses on the physiological role of antigen presentation
by MHCI- or MHCII-dressed cells, and also discusses differences and similarities between
trogocytosis and exosome-mediated transfer of MHC.
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INTRODUCTION
Intercellular transfer of MHC was first observed by Cone et al.
over 40 years ago (1). In this study, mouse T cells were adop-
tively transferred to MHC-mismatched mice, and the authors
surprisingly found the MHC of the recipient mice on trans-
ferred T cells (1). Since this seminal study, numerous others have
shown that the T cell receptor (TCR) rapidly (within minutes)
acquires MHC molecules from antigen-presenting cells (APCs) via
the immunological synapse formed at cell–cell contact area, and
that this phenomenon impacts T cell activation (2–8), although
the physiological relevance of this is still not fully understood.
This intercellular transfer of plasma membrane has been called
absorption, acquisition, nibbling, shaving, snatching, stripping,
or trogocytosis, which is from the ancient Greek Trogo, mean-
ing “gnaw” (9, 10). Among these names, trogocytosis is now most
commonly used. Several recent studies reported that trogocyto-
sis of MHC class I (MHCI) and MHC class II (MHCII) occurs
not only between T cells and APCs, but between a wide variety of
cell types including APCs–APCs, APCs–natural killer (NK) cells,
tumor cells–T or NK cells, etc. (10–14), suggesting that the type
of cell receiving such MHC may impact antigen-specific T cell
activation.
Intercellular transfer of MHC is mediated not only via trogo-
cytosis but also via exosomes, which are nano-sized membrane
vesicles released from various cells (12, 15). Because trogocytosis
generally occurs rapidly in a cell–cell contact-dependent manner,
it has been considered to be a distinct mechanism from exo-
some release (9, 16), although some aspects of trogocytosis and
exosome-mediated transfer are quite similar, as described below.
Trogocytosis- or exosome-mediated intercellular MHC transfer
can transiently generate MHC-dressed cells, which modulate T cell
activation (Table 1). For example, CD8+ cytotoxic T lymphocytes
(CTLs) dressed with APC-derived MHCI are lysed by neighboring
CTLs (2, 4). CD4+ T cells dressed with dendritic cell (DC)-derived
MHCII work as suppressor APCs (17, 18). These reports sug-
gest that DC-derived MHC molecules are functional on T cells
(Table 1), although some MHC molecules may be occupied by
the TCR. Likewise, DCs also acquire MHC molecules from neigh-
boring DCs, and the transferred MHC molecules are functional
on the recipient DCs. Because recent findings on T cells dressed
with MHC is well summarized by other review papers (11, 14),
this review focuses on the DCs or non-professional APCs dressed
with MHCI or MHCII, which acquire APC-like function, and also
discusses the differences and similarities between trogocytosis and
exosome-mediated transfer.
ANTIGEN PRESENTATION BY MHCI-DRESSED CELLS:
CROSS-DRESSING
Dendritic cells have long been known to present MHCI-bound
antigens to CD8+ T cells through two main pathways: direct
presentation of endogenous viral antigens when DCs are virally
infected (Figure 1A), and cross-presentation of exogenous anti-
gens from dying tumor cells and virally infected cells that are
phagocytosed and processed (57, 58) (Figure 1B). In addition to
these canonical antigen presentation pathways, several recent stud-
ies proposed a third pathway of antigen presentation in which DCs
acquire the preformed peptide–MHCI complexes from neighbor-
ing DCs or tumor cells and activate CD8+ T cells without any
further peptide processing (28, 29, 35, 36, 59, 60) (Figure 1C). This
third pathway of antigen presentation was coined “cross-dressing”
by Yewdell and Haerfar (61). Although the antigen presentation
by DCs dressed with MHCII is also called cross-dressing in some
papers (55, 56), this original meaning seems to be the dressed
MHCI-mediated antigen presentation (61). Dolan et al. clearly
demonstrated the existence of the cross-dressing pathway both
in vitro and in vivo (35). Specifically, it was shown that when H-
2q mouse bone marrow-derived DCs (BMDCs) were co-cultured
with dying H-2b tumor cell lines expressing ovalbumin (OVA),
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Table 1 | Overview of intercellular MHC transfer.
Donor cell Recipient cell Mechanism Function (Ref)
INTERCELLULAR MHCITRANSFER
APCs (DCs) CD8+ T cells Trogocytosis (TCR-mediated) Target for neighboring CTLs: fratricide (2, 4)
TCR downregulation (7)
Unknown (3)
Live tumor cells CD8+ T cells Trogocytosis (TCR-mediated) Target for neighboring CTLs: fratricide (19)
Enhancement of CTL activity? (20)
Suppression of CTL activity? (21)
Stripping MHCI off target tumor cells (8)
APCs CD4− CD8− Tregs Trogocytosis (TCR-mediated) Antigen presentation for CD8+ T cell suppression (22)
DCs CD4+ T cells Trogocytosis (TCR-mediated bystander) Antigen presentation for CD8+ T cell activation (23)
Live tumor cells NK cells Trogocytosis (KIR-mediated) Suppression of neighboring NK cells (24)
Unknown (25, 26)
Splenocytes NK cells Unknown Enhancement of killer activity (27)
DCs DCs Trogocytosis Antigen presentation for CD8+ T cell activation: cross-dressing (28–30)
DCs, ECs DCs Exosomes Antigen presentation for CD8+ T cell activation: cross-dressing (31, 32)
Live tumor cells DCs Exosomes Antigen presentation for CD8+ T cell activation (33)
Live tumor cells DCs Trogocytosis? Target for neighboring CTLs (34)
Dead tumor cells DCs, pDCs Trogocytosis Antigen presentation for CD8+ T cell activation (35–37)
INTERCELLULAR MHCIITRANSFER
mTECs Thymic DCs Unknown Antigen presentation for central tolerance (38–40)
APCs (DCs) CD4+ T cells Trogocytosis (TCR-mediated) Sustaining of TCR signaling (41, 42)
Antigen presentation for CD4+ T cell suppression (17, 18)
Antigen presentation for CD4+ T cell activation (43–45)
APCs (DCs) CD4+ T cells Exosomes Antigen presentation for CD4+ T cell suppression (46, 47)
Unknown (48)
APCs CD4+ Tregs Trogocytosis (TCR-mediated) Antigen presentation for CD4+ T cell suppression (44)
DCs CD8+ T cells Trogocytosis (TCR-mediated bystander) Antigen presentation for CD4+ T cell activation? (3, 49)
DCs NK cells Trogocytosis Antigen presentation for CD4+ T cell suppression (50)
DCs ILC2s Trogocytosis Antigen presentation for CD4+ T cell activation (51)
DCs LNSCs Trogocytosis and exosomes Antigen presentation for CD4+ T cell suppression (52)
DCs DCs Exosomes Antigen presentation for CD4+ T cell activation (31, 53, 54)
Dead tumor cells DCs Trogocytosis? Antigen presentation for CD4+ T cell activation (55)
APCs DCs Unknown No antigen-presenting activity (56)
APCs, antigen-presenting cells; CTLs; cytotoxic T lymphocytes; DCs, dendritic cells; ECs, endothelial cells; ILC2s, group 2 innate lymphoid cells; KIR, killer cell
immunoglobulin-like receptor; LNSCs, lymph node stromal cells; MHCI, MHC class I; MHCII, MHC class II; mTECs, medullary thymic epithelial cells; NK, natural killer;
pDCs, plasmacytoid DCs; TCR, T cell receptor; Tregs, regulatory T cells.
the H-2q BMDMs acquired the OVA peptide–H-2Kb complexes
from the tumor cells, and subsequently activated OT-I CD8+
T cells expressing the TCR that recognizes the OVA peptide on
H-2Kb (Figure 1C). Further, by analyzing OT-I proliferation in
CD11c-diphtheria toxin receptor (DTA) mice [in which CD11c+
DCs are removable by diphtheria toxin (DT) treatment] inocu-
lated with OVA/H-2Kb tumor cells, the authors demonstrated that
DCs are essential for OT-I proliferation in response to the tumor
cell-derived OVA peptide–H-2Kb complexes in vivo (35). Finally,
Wakim and Bevan highlighted the importance of cross-dressing
in mouse models of viral infection (29). The authors utilized
irradiated (Kd×Kb) F1 mice reconstituted with Kd CD11c-DTR
bone marrow (BM) cells, in which DCs have only Kd and are
removable by DT treatment. Following adoptive transfer of OT-I
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FIGURE 1 | Canonical and non-canonical antigen presentation pathways.
(A)When DCs are virally infected, these DCs present the endogenous viral
antigens on the endogenous MHCI molecules to CD8+ T cells. (B)When
certain DC subsets such as mouse CD8α+ DCs and human BDCA3+ DCs
engulf dying cells, these DCs can present the exogenous antigens on the
endogenous MHCI molecules to CD8+ T cells, which is called
cross-presentation. (C)When DCs acquire the exogenous antigen–MHCI
complexes from neighboring DCs and/or tumor cells, these DCs activate
CD8+ T cells via the dressed MHCI without requiring processing, which is
called cross-dressing. (D)When DCs engulf dying cells, these DCs present
the exogenous antigens on the endogenous MHCII molecules to CD4+
T cells. This is the normal presentation of exogenous antigens. (E)When DCs
or ILC2s expressing co-stimulatory molecules acquire the exogenous
antigen–MHCII complexes from neighboring DCs, these MHCII-dressed cells
induce CD4+ T cell activation. On the contrary, when NK cells or LNSCs not
expressing co-stimulatory molecules acquire the exogenous antigen–MHCII
complexes from neighboring DCs, these MHCII-dressed cells suppress CD4+
T cell activation. Intercellular MHC transfer is mediated via trogocytosis and/or
exosomes. Trogocytosis is defined as an intercellular transfer of plasma
membrane fragments that occurs rapidly (within minutes) in a cell–cell
contact-dependent manner. Exosomes can be transferred at a distance and
diffuse slowly (over several hours).
cells into these mice and infection with vesicular stomatitis virus
expressing OVA, the authors demonstrated that DCs acquired
the OVA peptide–Kb complexes from the virally infected cells,
and stimulated memory OT-I CD8+ T cells, but not naïve OT-I
CD8+ T cells, in vivo. These results suggest that cross-dressing may
contribute to effective anti-viral immune responses.
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Among mouse DC subsets, CD8α− DCs show higher cross-
dressing of neighboring DC-derived MHCI compared with
CD8α+ DCs (28–30), while CD8α+ DCs are essential for the
cross-dressing of plasmid DNA vaccine antigens in vivo (36). This
apparent discrepancy may be ascribed to the difference in type of
donor cells (i.e., live DCs, dying tumor cells, etc.) that DCs acquire
MHCI from. In addition to these conventional DCs, plasmacytoid
DCs (pDCs) are a unique DC subset producing a large amount
of type I interferon in response to microbial infection (62), and
human pDCs have been also reported to acquire antigen–MHC
complexes from tumor cells and to stimulate HLA-A2-restricted
T cell proliferation (37).
The frequency of cross-dressing in vivo remains to be deter-
mined. A number of early reports investigating the cross-
presentation pathway (Figure 1B) may have excluded the possi-
bility of the recently emerged cross-dressing pathway (Figure 1C)
(57, 58, 63). For example, Kurts et al. engineered an elegant mouse
model with which to demonstrate the cross-presentation path-
way (64, 65). First, the authors generated the RIP (rat insulin
promoter)-mOVA transgenic Kb mouse that expresses membrane-
bound form of OVA in pancreatic islet β cells and renal proximal
tubular cells. RIP-mOVA mice were lethally irradiated and received
Kb BM cells or Kbm1 BM cells, where Kbm1 is a Kb mutant that does
not present OVA peptide to OT-I cells. After adoptive transfer of
OT-I cells into these mice, the authors observed the migration
of OT-I cells into renal lymph nodes (LN) of RIP-mOVA mice
receiving Kb BM cells, but not of the mice receiving Kbm1 BM cells
(64, 65). These results clearly indicate that endogenous MHCI on
BM-derived APCs is essential for exogenous antigen presentation.
If cross-dressing occurred in this model, the authors would have
observed OT-I cell migration in the RIP-mOVA mice receiving
Kbm1 BM cells.
On the other hand, several early studies showed that cross-
presentation was not required for priming of CD8+ T cells
against some exogenous antigens (33, 66, 67). For example, Kundig
et al. reported that tumor cells directly induce CTLs in vivo,
and host MHCI is not involved in this process (66). Wolfers
et al. also observed that immunogenic tumor cells directly prime
tumor-specific T cells in TAP (transporter associated with antigen
presentation)-deficient mice (33). However, these studies do not
exclude the possibility that host DCs acquire MHCI from tumor
cells for the antigen presentation.
Taken together, it is possible that cross-dressing may occur
in vivo only under pathological conditions such as during viral
infection and cancer. Further, the phenomenon of cross-dressing
may explain exogenous antigen presentation to CD8+ T cells in
mouse models where cross-presentation does not occur.
It is also intriguing to address whether intercellular MHCI
transfer impacts donor cell function. As described below, only
a small percent of MHCI on donor cells can be transferred to
recipient cells (2, 7). Thus, the donor cells seem to retain a suffi-
cient amount of MHCI on their cell surface even after the transfer.
However, interestingly, Chung et al. recently reported that low-
avidity CTLs strip MHCI off target tumor cells via the mechanism
of trogocytosis without killing, resulting in an interference with
high-avidity CTLs in tumor lysis (8). It remains unknown whether
donor DCs lose the antigen-presenting activity after the release of
their MHC molecules to recipient DCs.
ANTIGEN PRESENTATION BY MHCII-DRESSED CELLS
MHCII is restrictedly expressed on professional APCs where it
presents exogenous antigens to CD4+ T cells (Figure 1D) (68). In
the thymus, intercellular MHCII transfer was observed between
medullary thymic epithelial cells (mTECs) and DCs (38, 39). This
process is proposed to increase the probability of autoreactive
T cells encountering rare antigens for tolerance induction (40,
69). In the periphery, during the interaction between APCs and
CD4+ T cells, the TCR on the latter trogocytoses MHCII. Because
T cells do not express co-stimulatory molecules, MHCII-dressed
CD4+ T cells induce tolerance in neighboring CD4+ T cells, ter-
minating these T cell responses (17, 18). On the contrary, several
reports show that CD4+ T cells trogocytose not only MHCII but
also CD80, and these CD4+ T cells dressed with MHCII and
CD80 work as APCs for the amplification of CD4+ T cell prolif-
eration (43–45). Together, existence of co-stimulatory molecules
on MHCII-dressed cells determines these cell functions. Several
recent studies reported that intercellular MHCII transfer occurs
not only between DCs and T cells, but also between various cells
such as DCs and DCs (31, 53, 54, 56), DCs and NK cells (50), DCs
and lymph node stromal cells (LNSCs) (52), and DCs and group
2 innate lymphoid cells (ILC2s) (51) (Table 1).
The expression and function of MHCII on mouse NK cells
have not been fully understood. We previously showed that mouse
conventional NK cells do not synthesize MHCII, rather these cells
rapidly acquire MHCII from co-cultured DCs (50). Moreover,
NK cells dressed with the OVA peptide–MHCII complexes nei-
ther express nor acquire co-stimulatory molecules such as CD80
and CD86, and therefore, suppress but do not induce OT-II CD4+
T cell proliferation, suggesting a negative regulation of acquired
immunity by NK cells (Figure 1E) (50). NK cells also acquire
MHCII from co-cultured B cells; however, the level of MHCII on
these NK cells was lower than that on NK cells co-cultured with
DCs, suggesting that NK cells preferentially acquire MHCII from
DCs (50).
LNSCs have been considered to only play an architectural role in
LN construction and homeostasis; however, it is now known that
these cells play an important role in peripheral T cell tolerance
(70). Dubrot et al. recently showed that LNSCs per se synthesize
MHCII,but also acquire MHCII from DCs in vitro and in vivo (52).
Like MHCII-dressed NK cells (50), MHCII-dressed LNSCs neither
express nor acquire co-stimulatory molecules, resulting in promo-
tion of CD4+ T cell apoptosis rather than proliferation. These data
suggest that LNSCs maintain peripheral CD4+ T cell tolerance via
DC-derived peptide–MHCII complexes in LNs (Figure 1E).
ILC2s are recently discovered innate lymphoid cells that pro-
duce IL-5, IL-9, and IL-13 and support type-2 immune responses
such as allergy and anti-parasite immunity (71). Nevertheless,
antigen presentation by ILC2 is not fully understood. Very recently,
Oliphant et al. showed that ILC2s express MHCII and also acquire
MHCII through trogocytosis in vivo (51). ILC2s also express
CD80 and CD86 and polarize CD4+ T cells toward a Th2 pheno-
type by antigen presentation in conjunction with type-2 cytokine
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production. Thus, the dressed MHCII may contribute to type-2
immune responses in vivo (Figure 1E).
Given that intercellular transfer of MHCII is observed between
DCs and various immune cells, it would be intriguing to address
the diffusion of APC-derived MHCII in vivo. In fact, such experi-
ments may uncover a novel cell subset capable of activating or reg-
ulating CD4+ T cells via the preformed antigen peptide–MHCII
complexes.
MECHANISM OF MHC TROGOCYTOSIS
DO DC RECEPTORS MEDIATE MHC TROGOCYTOSIS?
The molecular mechanism underlying the trogocytosis of MHC
by T cells has been well studied (3, 6, 7); however, the mech-
anism controlling this process in DCs remains to be identified.
Of note, Martinez-Martin et al. have reported that TCRs trogo-
cytose MHCI from APCs via small GTPases such as TC21 and
RhoG previously known to be associated with phagocytosis. This
finding led to the hypothesis that trogotytosis may actually repre-
sent immature phagocytosis (7). Therefore, DCs may trogocytose
MHC by using phagocytic receptors. Harshyne et al. previously
reported that plasma membrane transfer between live monkey
DCs was inhibited in vitro by a polyanionic reagent, suggesting
that scavenger receptors may contribute to the membrane trans-
fer (60), although this has not been confirmed. Li et al. showed
that mouse splenic CD8α+ DCs are essential for cross-dressing of
plasmid DNA vaccine antigen in vivo (36). Of note, CD8α+ DCs
are a unique DC subset that efficiently phagocytose apoptotic cells
and perform cross-presentation (57, 58). In addition, these DCs
have been reported to recognize dying cells via CLEC9A/DNGR-1
(72, 73), Treml4 (74), and Tim-3 (75); therefore, these receptors
may acquire MHCI from dying cells. In contrast, Smyth et al., and
Wakim and Bevan independently reported that splenic CD8α−
DCs, rather than CD8α+ DCs, showed more efficient cross-
dressing of neighboring DC-derived MHCI (28–30). In these
studies it remains unknown whether the cross-dressing activity
is ascribed to the ability to acquire MHCI. Thus, although T cells
solely use the TCR to acquire MHC (4,5,14),DCs may use different
receptors to acquire MHCI from various donor cells.
Additionally, it is unknown if any membrane protein other than
MHC is acquired by DCs, although it is unlikely that DCs specifi-
cally recognize and acquire only MHCI/II. More likely, DCs nibble
a whole membrane fragment at the site of cell–cell contact similar
to a model that has been proposed for T cell trogocytosis (4, 16).
Indeed, the TCR on CD8+ T cells binds MHCI on DCs, and nib-
bles the MHCI-containing membrane fragments, in which MHCII
is also contained (3, 49). Likewise, CD4+ T cells trogocytose not
only MHCII but also MHCI from DCs through the bystander
mechanism (23) (Table 1). Thus, any membrane proteins at the
cell–cell contact area would be transferred to DCs. The reason only
MHC molecules may appear to be transferred is probably because
MHC molecules are highly expressed on donor cells and are easily
detected. Only a small percent (at most 10%) of highly expressed
cell surface molecules on donor cells can be transferred to recipi-
ent cells, as shown by the fluorescence intensity of flow cytometry
and confocal microscopy data in many reports (2, 7, 29, 35, 36, 50,
76). Therefore, it is difficult to detect the trogocytosis of molecules
with low expression on donor cells, even if trogocytosis occurs.
Identification of the DC receptor(s) and ligand(s) required for the
trogocytosis of MHCI will resolve these issues.
IS TROGOCYTOSIS DIFFERENT FROM EXOSOME-MEDIATED TRANSFER?
Exosomes are nano-sized membrane vesicles released by a wide
variety of cell types (15). Many reports have shown that MHCI-
bearing exosomes are secreted from APCs and several tumor cell
lines, and that these exosomes play important roles in anti-tumor
immunity (15, 77). For example, tumor-derived exosomes can
activate CD8+ T cells when co-cultured with DCs (33, 78). In these
experiments, the exosomal MHCI is not critical, suggesting that
tumor antigen alone, but not tumor-derived MHCI, is required
for DC-mediated antigen presentation (33, 78). Meanwhile, DC-
derived exosomes bear MHCI and co-stimulatory molecules, and
per se are able to induce CD8+ T cell proliferation (15).
Wakim and Bevan conducted experiments to carefully address
the possibility that cross-dressing is mediated via MHCI-bearing
exosomes (29). In these experiments, it was observed that DC-
derived exosomes alone, but not those co-cultured with H-2Kbm1
DCs, induce OT-I CD8+ T cell proliferation, leading to the specu-
lation that exosomes may be internalized by and degraded within
DCs. Furthermore, the authors showed that DCs co-cultured at a
distance (using a transwell system) lost cross-dressing activity, sug-
gesting that the intercellular transfer of the peptide–MHCI com-
plexes between DCs is mediated via cell–cell contact-dependent
trogocytosis rather than exosomes (29).
MHCII-bearing exosomes are also secreted from DCs and
possess functional capacity (15, 79). For instance, Théry et al.
reported that DC-derived MHCII-bearing exosomes acquired by
MHCII-deficient DCs can stimulate antigen-specific CD4+ T cell
proliferation in vitro (54). Dubrot et al. observed that MHCII
transfer from DCs to LNSCs is cell–cell contact-dependent, sug-
gesting trogocytosis. Nevertheless, the authors do not exclude the
possibility that DC-derived exosomes may also contribute to this
process because LNSCs co-cultured with DC-derived exosomes
also became MHCII-positive and activated CD4+ T cells (52).
As described above, trogocytosis was originally defined as an
intercellular transfer of plasma membrane that occurs rapidly
(within minutes) in a cell–cell contact-dependent manner. In con-
trast, exosomes can be transferred at a distance and diffuse slowly
(over several hours) (10, 12). Indeed, the TCR and NK receptors
acquire MHC and related molecules from donor cells within min-
utes in a cell–cell contact-dependent manner, and this does not
occur when donor cells and recipient cells are co-cultured at a
distance in a transwell plate (2, 7, 50, 76, 80), which is typical of
trogocytosis. However, acquisition of MHC by DCs takes several
hours (28, 29, 31, 35, 36). To make matters more complicated, Mit-
telbrunn et al. recently showed that T cells secrete exosomes when
a functional immunological synapse is formed at the APC contact
site, and that this release of exosomes is abrogated by a transwell
culture system (81). Together, these reports make it difficult to
discriminate between trogocytosis and exosome-mediated trans-
fer. As there are a variety of types of exosomes and exosome-like
microvesicles (15), it is reasonable to hypothesize that trogocy-
tosis may actually be mediated via several unique mechanisms,
and furthermore, that some instances of exosome transfer and
trogocytosis may be mediated via a shared mechanism.
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CONCLUSION
There is no doubt that DCs play a crucial role in antigen process-
ing and presentation. However, it was unforeseen that the antigen
peptide–MHC complexes on DCs can be transferred to neigh-
boring DCs or non-APCs where the preformed peptide–MHC
complexes are involved in antigen-specific T cell activation with-
out requirement for further processing. These MHC-dressed cells
expressing or not expressing co-stimulatory molecules could con-
tribute to T cell activation or suppression, respectively, which may
play an important role in fine-tuning signals from DCs in vivo.
As the occurrence of this transfer has been well established, the
leading question remaining is how exactly the MHC molecules
are transferred. It also remains unknown whether donor cell-
derived membrane fragments including MHC can be fused or are
merely attached to the membrane of recipient cells. Identification
of the molecular mechanisms underlying MHC trogocytosis and
exosome transfer will enable us to perturb these pathways and fur-
ther address the physiological relevance of non-canonical antigen
presentation in vivo.
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